GlaxoSmithKline has rounded up some early preclinical projects in its inaugural Discovery Fast Track competition, hand-picking academic scientists for a chance to partner up and kick-start their research into a development program.
Novartis is bringing the ax down on close to 400 R&D jobs at its respiratory R&D center in West Sussex in the U.K., signaling that the restructuring is part of a broader global realignment.
After ditching a planned private raise, Utah's Lipocine is looking to the boiling public market for biotechs, filing an S-1 for $11.5 million to fund its oral testosterone replacement therapy.
With healthcare officials around the world ringing alarm bells over a weak global pipeline of antibiotics, Roche's pRED group is making good on its promised return to the field with a $560 million development deal, partnering up with a Phase II program underway at Polyphor.
2012 Fierce 15 member Celladon has boosted its IPO goals, seeking as much as $92 million to help get its gene therapy for heart failure through a Phase IIb study and into Phase III.
A team from IBM Research and the Institute of Bioengineering and Nanotechnology in Singapore have designed a Vitamin E-based hydrogel that can release Roche's cancer antibody Herceptin under the skin for several weeks.
Fidelity Biosciences is placing a big bet on gene therapy, funding the launch of startup Dimension Therapeutics with some licensed patents and a plan to develop novel treatments for hemophilia.
GLP-1 drugs have long been one of the hottest targets in diabetes R&D, attracting the attention of the all of the giants that play in this blockbuster market. But now Roche has its eye on an early-stage program that could do GLP-1 drugs one better.
A pair of scientifists with deep roots in the Alzheimer's field is partnering up with two high-profile antibody development experts with a well-developed platform technology to launch a new biotech with ambitious plans to build a pipeline of new medications to combat the memory-wasting disease. And they're getting $10 million in seed cash from two marquee venture groups to get everything going.
Tantalized by various megablockbuster projections for the PCSK9 field of cholesterol drugs, Pfizer has mapped out one of the most ambitious late-stage programs in the industry for RN-316. This week, the pharma giant spelled out plans for a massive cardiovascular outcomes trial to prove to regulators and payers alike that the drug not only works as advertised, but delivers real value to patients.